Protective effect of erythropoietin on myocardial infarction in rats by inhibition of caspase-12 expression
- Authors: Shaoxiang Weng, Xiaoqing Zhu, Yue Jin, Ting Wang, He Huang
Published online on: Friday, June 3, 2011
- Pages: 833-836
- DOI: 10.3892/etm.2011.280
Myocardial infarction results in insufficient blood supply, decreasing the function of myocardial cells and ventricular remodeling, eventually leading to heart failure (1). Myocardial cell apoptosis is a critical feature of myocardial infarction (2). Erythropoietin (EPO) is a glycoprotein hormone produced by the kidney and fetal liver (3). In recent studies, EPO was shown to have protective effects against ischemic injury in the brain (4), spinal cord (5), kidney (6), and even in the myocardium (7). Clinical application of EPO to treat anemia associated with congestive heart failure was found to significantly improve cardiac function in these patients (8), and increasing evidence suggests that EPO increases the ability of myocardial cells to endure ischemic tolerance of hypoxia. Current findings suggest that the protective effects of EPO on myocardial infarction depend on the anti-apoptotic effect of certain cytokines, but its exact mechanism remains unknown (9).
The endoplasmic reticulum (ER) has received much attention recently for its role in signal transduction relevant to cell survival and death. Myocardial infarction conditions induce Ca2+ overload and/or accumulation of unfolding or misfolding proteins within the ER. ER stress induces multiple responses, including adaptive changes in translation, protein folding, secretion and degradation. Prolonged ER stress triggers apoptosis by induction of C/EBP homologous protein (CHOP), activation of c-JUN NH2-terminal kinase (JNK) and finally production of pro-apoptotic factors (caspase-12), which may contribute to the development of diabetic nephropathy (10). In addition, caspase-12 causes ER stress-induced apoptosis, which is a feature of ischemia/reperfusion (I/R) injury, and thus suppressing ER stress may protect the myocardium from I/R injury (11).
In the present study, we hypothesized that the protective effect of EPO against ischemic injury in the myocardium was through the reduction of ER stress-induced apoptosis. We induced myocardial infarction in a rat model by ligating the left anterior descending coronary artery and examined systolic and diastolic function 4 weeks after myocardial infarction, as well as myocardial fibrosis, apoptosis, angiogenesis and expression of caspase-12 in myocardial infarction myocardium, non-infarcted myocardium and myocardial infarction myocardium treated with EPO. The aim of this study was to determine the relationship between a decrease in caspase-12 expression in the heart and the protective effects of EPO on myocardial infarction.
Materials and methods
Sprague-Dawley male rats were purchased from the Experimental Animal Centre of Zhejiang University (Hangzhou, China). Recombinant human erythropoietin (rhEPO) was obtained from Shenyang Sunshine Pharmaceutical Co., Ltd. (Shenyang, China). Monoclonal caspase-12 antibody was purchased from Abcam Company (Cambridge, MA, USA). Langendorff heart perfusion apparatus was purchased from Nanjing Medease Science and Technology Co., Ltd. (Nanjing, China).
Animal model induction
Thirty male Sprague-Dawley rats with a body weight of ∼210 g were used for this study and were randomly divided into three groups (10 rats/group): sham-operation group, myocardial infarction group and EPO treatment group. Under pentobarbital anesthesia, rats were intubated and mechanically ventilated with a Harvard respirator. Physiological arterial blood gas levels were maintained by adjusting the respirator and oxygen supplement. Hearts were exposed via the left thoracotomy, and a coronary snare was prepared around the left anterior artery. In the myocardial infarction and EPO treatment groups, the left anterior descending coronary artery was ligatured between the pulmonary cone and the left atrial appendage, and the left anterior descending coronary artery blood supply region became white. Subsequently, the rats were intraperitoneally injected with 4.0×106 U of penicillin to prevent infection, and revived at 30°C, while the sham-operation rats only received thoracotomy. After the operation, the EPO group rats received an intraperitoneal injection of EPO (1×103 IU/kg/day), while the sham-operation and myocardial infarction group rats received an intraperitoneal injection of normal saline (1 ml/kg/day) for 4 weeks.
Coronary perfusion using the Langendorff system with modified Krebs-Henseleit (KH) solution containing 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 24.8 NaHCO3, 1.2 KH2PO4 and 10 glucose (in mM) was carried out. After 4 weeks, five isolated hearts in each group were extracted. A KH buffer-filled latex balloon was inserted into the left ventricle (LV) and was adjusted to 5–10 mmHg of the left ventricular end-diastolic pressure (LVEDP) at the beginning of the experiment. Each isolated heart was perfused with 37°C oxygenated (95% O2-5% CO2) modified KH buffer. Left ventricular systolic pressure (LVSP) and LVEDP were recorded with the Langendorff heart perfusion apparatus system by averaging the values for ten beats. Left ventricular diastolic pressure (LVDP) was calculated as follows: LVDP = LVSP - LVEDP.
Immunohistochemistry and H&E staining
Immunohistochemistry was used to localize the caspase-12 antigen. Five rats from each group were anesthetized with a lethal dose of pentobarbital. Their thoracic cavities were then opened and perfused intracardially with normal saline. Following saline perfusion, the animals were perfused with 300–400 ml of fixative containing 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). After perfusion, the heart of each rat was removed, fixed in the same fixative for 4 h and then placed in 30% phosphate-buffered sucrose until the tissue sank. Tissue sections (8 μm) were cut on a freezing microtome through the coronary planes of the heart. Sections were then rinsed in 0.01 M phosphate-buffered saline (PBS) and mounted onto 0.02% poly-l-lysine-coated slides.
Tissue sections were washed in PBS, incubated in 1% bovine serum albumin (BSA) for 30 min, and then incubated overnight at 4°C in the primary antibody (monoclonal caspase-12 antibody) plus 1% BSA in PBS. The dilution of the primary antibody was 1:100. Control sections were incubated in PBS alone. The next day, the sections were incubated in a biotinylated goat anti-mouse secondary antibody (diluted to 1:200 in PBS), and subsequently in an avidin-horseradish peroxidase solution. Immunolabelling was visualized with 0.05% DAB (Sigma, St. Louis, MO, USA) plus 0.3% H2O2 in PBS. The sections were then dehydrated through ethanol and xylene before being cover-slipped with Permount™. H&E staining was also applied to determine morphological changes.
For immunohistochemistry, the left ventricular tissues were selected on each slide and examined at a magnification of x400 with a UTHSCSA Image Tool 3.0 (University of Texas Medical School at San Antonio, San Antonio, TX, USA). The number and optical density of the caspase-12-positive cells were measured.
All data are the means ± SD. Statistical analysis was performed using SPSS® for Windows® version 12.0 statistical software (SPSS Inc., St. Louis, MO, USA). The significance of any differences between the groups was evaluated using the one-way ANOVA. P-values <0.05 were considered significant.
LVDP of the myocardial infarction group rats was significantly decreased to 68.5±4.1 mmHg, while that in the sham-operation rats was 91.3±7.9 mmHg. Treatment with EPO for 4 weeks caused a statistically significant increase in cardiac functional recovery improving the LVDP to 82.9±8.35 mmHg (P<0.01) in the EPO treatment group when compared to that in the myocardial infarction group (Fig. 1).
LVDP in each group 4 weeks after operation. (A) Control, (B) myocardial infarction and (C) EPO treatment rats. *P<0.01 vs. control; #P<0.01 vs. myocardial infarction.
Heart pathological changes
As shown in Fig. 2B, infarction, myocardial fibrosis, the collagen deposition area and the remnants of cardiac disorder were substantially severe in the myocardial infarction group rats. Fig. 2C demonstrates a notably higher number of small vessels around the infarcted myocardium in the EPO treatment group rats than in the myocardial infarction group rats. The myocardial interstitial fibrosis area was also improved in the EPO treatment group rats (Fig. 2).
Pathological changes in the myocardium of (A) a control rat, (B) a myocardial infarction rat and (C) an EPO treatment rat 4 weeks after operation by H&E staining.
Immunohistochemical staining of caspase-12 localization
Fig. 2 shows light photomicrographs of caspase-12 immunohistochemical staining of the myocardium in the three groups of rats. In heart tissues from the myocardial infarction rats, the myocardium underwent fibrosis and structural rarefaction. Myocardium that stained positive for caspase-12 showed buff-colored granules with DAB staining. The myocardium showed increased caspase-12 expression in the myocardial infarction group when compared to the control group. Also, the EPO-treated rats had a significantly decreased number of caspase-12-positive cells and decreased optical density of the caspase-12 immunostained myocardium compared to the myocardial infarction rats (P<0.01) (Figs. 3 and 4).
Light photomicrographs of caspase-12 immunohistochemical staining of the myocardium from (A) a control rat, (B) a myocardial infarction rat and (C) an EPO treatment rat.
Comparison of the expression of caspase-12 in the myocardium of (A) a control rat, (B) a myocardial infarction rat and (C) an EPO treatment rat. *P<0.01 vs. control group; #P<0.01 vs. myocardial infarction group.
The ER is the site for the proper folding and assembly of membrane-localized proteins and those destined for secretion. It is also a regulator of intracellular calcium (12). Various pathophysiological conditions induce Ca2+ overload and/or accumulation of unfolding or misfolding proteins within the ER, a condition referred to as ER stress (13). ER stress-induced apoptosis is believed to be associated with several pathological processes, including diabetes (14), ischemia-reperfusion injury (7), Alzheimer's disease and Parkinson's disease (15,16). Researchers have already found that myocardial ischemia provokes ER stress which results in the apoptosis of myocardial and coronary endothelial cells; in addition, caspase-12 plays a major role in this apoptosis induction (17,18). Our results demonstrated that the expression of caspase-12 was significantly elevated in the myocardial ischemic areas compared to the normal areas. Also, apoptosis of myocardial cells increased accompanied by myocardial fibrosis in the myocardial ischemic areas which caused cardiac dysfunction.
EPO has emerged as a promising candidate for the treatment of acute ischemic heart disease (7). Apart from its hematopoietic effects, EPO exhibits anti-apoptotic effects, particularly under ischemic conditions, and attenuates oxidative stress (19). The binding of EPO to the EPO receptor leads to a hemodimerization, with subsequent activation of janus kinase (26). EPO signaling involves multiple pathways, including activation of STAT 5, activation of proteins with Src homology, such as PI3 kinase, and activation of ras/MAP kinases (20,21). In the present study, EPO improved myocardial contractility, reduced celluar damage and apoptosis, increased neovascularization, and improved and decreased the expression of caspase-12 in a rat model of myocardial infarction. These results suggest that the mechanism of cardiac improvement by application of EPO may block signal transduction in ER stress via reduction of the expression of caspase-12, which has a beneficial effect on myocardial protection.
The present study used the Langendorff system to record the LVDP and immunohistochemistry to determine the expression of caspase-12 protein in the heart after 4 weeks of myocardial infarction induction, and to demonstrate the protective effect of EPO on myocardial infarction. There was less function reduction and structural damage to the heart in the EPO-treated group than in the myocardial infarction group. We demonstrated that EPO treatment of myocardial infarction prevents the appearance of subsequent clinical symptoms by reversing the functional and morphological abnormalities in the myocardial infarction heart in a rat model through abrogation of the myocardial infarction-induced increase in caspase-12 expression and prevented ER stress-induced apoptosis after myocardial infarction. This study provides the experimental basis for EPO treatment for myocardial infarction, while the exact mechanism of action will be the subject of further investigation.